CYP2A7 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2753072	0.56	3/20
SCHEMBL2752346	0.52	3/20
SCHEMBL2752131	0.52	3/20
SCHEMBL1165314	0.47	3/20
SCHEMBL971260	0.42	3/20
SCHEMBL2749440	0.42	3/20
SCHEMBL2752725	0.41	3/20
SCHEMBL2091704	0.41	3/20
SCHEMBL971261	0.40	3/20
Trifluoroacetic Acid (SCHEMBL2566375)	0.90	2/20
Trifluoroacetic Acid (SCHEMBL2592428)	0.90	2/20
Trifluoroacetic Acid (SCHEMBL2570005)	0.89	2/20
SCHEMBL2584612	0.79	2/20
SCHEMBL2407878	0.74	2/20
SCHEMBL196765	0.73	2/20
SCHEMBL2580241	0.72	2/20
Trifluoroacetic Acid (SCHEMBL2592437)	0.70	2/20
SCHEMBL2582318	0.68	2/20
SCHEMBL1180429	0.67	2/20
SCHEMBL1181635	0.67	2/20

Clinical trials — most relevant to CYP2A7 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies	PHASE4	RECRUITING
Cholestatic Drug-induced Liver Injury	PHASE4	UNKNOWN
Physiological Study of the Human CYP3A Activity (PiSA)	PHASE4	COMPLETED
Tamoxifen Citrate in Patients With Breast Cancer	PHASE3	UNKNOWN
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL	PHASE1/PHASE2	UNKNOWN
Repeat Dose Safety and Efficacy Study for Compound to Treat Anemia	PHASE2	COMPLETED
Efficacy and Safety of 3D185 Monotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Cholangiocarcinoma	PHASE2	NOT_YET_RECRUITING
Oral Cannabidiol for Opioid Withdrawal	PHASE1/PHASE2	COMPLETED
3 Month PHI PAD PoM Study	PHASE2	COMPLETED
A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma	PHASE1/PHASE2	UNKNOWN
Diindolylmethane in Treating Patients Undergoing Surgery for Stage I or Stage II Prostate Cancer	PHASE1	COMPLETED
A Phase I First-in-Human Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of SWA1211 Tablets in Subjects With Advanced Solid Tumors	PHASE1	RECRUITING
A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease	PHASE1	COMPLETED
Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects	PHASE1	COMPLETED
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors	PHASE1	UNKNOWN
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects	PHASE1	NOT_YET_RECRUITING
Alcohol Inhibits Drug Metabolism by Carboxylesterases	PHASE1	COMPLETED
Contribution of UGT2B17 to the Pharmacokinetics of Diclofenac	EARLY_PHASE1	RECRUITING
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
Genetic Polymorphisms in UGT1A6 and UGT2B7 in Asian Population: Association With Lung Cancer Phenotype	nan	UNKNOWN
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients	nan	COMPLETED
Biomarkers of CYP2D6 and CYP3A4 Variability in Pediatrics	nan	COMPLETED
Optimisation of Nutrition and Medication for Acutely Admitted Older Medical Patients	nan	UNKNOWN
CYP2D6 Screening for Adverse Drug Reactions to Codeine in Breast Milk	nan	COMPLETED
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis	nan	COMPLETED
CYP2D6 Genotyping by AmpliChipTM CYP450 for Tamoxifen-Treated Breast Cancer Patients	nan	UNKNOWN
Effects of CYP2B6 Genetic Polymorphisms on Efavirenz Pharmacokinetics	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CYP2A7 binder may also engage these)

Protein	Name	Similarity
P15123	—	1.000	P15123 →
CYP2A13	Cytochrome P450 2A13	1.000	landscape →
P20812	—	1.000	P20812 →
P33264	—	1.000	P33264 →
CYP2C19	Cytochrome P450 2C19	1.000	landscape →
CYP2A6	Cytochrome P450 2A6	0.999	landscape →
P00179	—	0.999	P00179 →
P20852	—	0.999	P20852 →
P33263	—	0.998	P33263 →
P00181	—	0.997	P00181 →
Q05556	—	0.997	Q05556 →
Q64583	—	0.997	Q64583 →
Q05555	—	0.997	Q05555 →
P00180	—	0.997	P00180 →
Q08078	—	0.996	Q08078 →
O55071	—	0.996	O55071 →
P17666	—	0.996	P17666 →
P33272	—	0.996	P33272 →
P10610	—	0.996	P10610 →
P00176	—	0.996	P00176 →
P33265	—	0.995	P33265 →
P56656	—	0.995	P56656 →
P15392	—	0.995	P15392 →
CYP2C18	Cytochrome P450 2C18	0.995	landscape →
O18809	—	0.995	O18809 →
CYP2C8	Cytochrome P450 2C8	0.995	landscape →
P24460	—	0.994	P24460 →
P56654	—	0.994	P56654 →
Q64458	—	0.994	Q64458 →
P12790	—	0.994	P12790 →